advertisement
Abstract #14526 Published in IGR 8-4
Red blood cell (RBC) surface acetylcholinesterase showing a hemorheological pattern during glaucoma treatment
Cicco G; Vetrugno M; Rotelli MT; Sborgia G; Pennetta M; Vico PP; Memeo V; Nitti L; Sborgia CClinical Hemorheology and Microcirculation 2006; 35: 149-154
BACKGROUND: Glaucoma is currently attributed to two different possible pathogenetic mechanisms: mechanical (the ocular damage is induced by physical injury), and vascular (the ocular damage is sustained by ischemia of the optic nerve head). AIM: We considered the possibility that several anti-glaucoma drugs (beta-blockers, carbonic anhydrase inhibitors and prostaglandins) could have an influence on optic nerve head hemorheology and oxygen supply. MATERIALS AND METHOD: We studied 4 groups of 10 subjects each: a control group, and 3 primary open angle glaucoma (POAG) groups, treated with topical beta-blockers, (10 patients), carbonic anhydrase inhibitors (CAI), and prostaglandin analogs (PG), respectively. In these 4 groups we investigated the RBC surface AchE and cytosolic calcium levels in order to assess their possible influence on the hemorheology and microcirculation in optic nerve head blood perfusion. RESULTS: A significant correlation (p < 0.048) was found between the RBC surface acetylcholinesterase and RBC intracytosolic calcium values in patients with POAG treated with beta-blockers. We found no significant correlation (p = n.s.) between the same patterns in the other Groups or in Controls. CONCLUSION: These data indicate that CAI and PG drugs do not interfere with AchE in POAG patients, whereas beta-blockers negatively affect the RBC deformability.
Dr. G. Cicco, CEMOT, Universita degli Studi di Bari, piazza G. Cesare, 11, 70124 Bari, Italy
Classification:
6.11 Bloodflow measurements (Part of: 6 Clinical examination methods)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
